SecBot SecBot

AIM

AIM ImmunoTech Inc.
NYSE· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0000946644 Biotech & Drug Discovery
$0.1600 +0.00 (+0.00%)
Oct 23 4:00 PM ET · prev $0.1600
Market cap
$6.4M
Nano cap
Consensus
Buy
83% Buy or better · 6 analysts
Median target
🔒 Subscribers only
1 year
−94.0%
from $2.68 · Oct 24
30 days
−20.0%
from $0.2000
52-week range
$0.1600–2.68
−94% from high · low Oct 14
Avg volume 20D
785.9K
Sep 29 spike 2.63M
Short interest
1.41M
≈3.5% of shares · −49.1%
Days to cover
1.0
at average volume
Insider net
+$18.5K
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
20
analyzed by SecBot
SecBot read BEARISH 8 reports · 90 days
Balance 3 bearish · 0 bullish · 1 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 5/8 ·Next Earnings date, Nov 16, 2026
Strongest BEARISH AIM ImmunoTech converted approximately $400,000 of its existing promissory note with Streeterville Capital…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $18.5K at an average $0.1970. No open-market sales. Price is 19% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 4 added (0 new), 0 trimmed or exited.

  • AnalystsBULLISH

    5 of 6 rate it Buy or better.

  • Short sellersCOVERING

    Short interest −49.1% to 1.41M shares. 1.0 days to cover, ≈3.5% of shares.

  • TrendDOWNTREND

    23% below its 50-day average. New closing low $0.1600 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
JANE STREET GROUP, LLCDOUBLED807,885$229.4K
MORGAN STANLEYDOUBLED50,864$14.4K
GEODE CAPITAL MANAGEMENT, LLCADD46,003$13.1K
UBS Group AGDOUBLED28,931$8.2K
GEODE CAPITAL MANAGEMENT, LLCADD29,918$17.5K
UBS Group AGNEAR_EXIT1$1.00
UBS Group AGTRIM304$833.00
BANK OF AMERICA CORP /DE/DOUBLED27$74.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

6 analysts
Buy 83% rate it Buy or better
Strong Buy1Buy4Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Aug 20, 2026Ascendiant Capital
MAINTAIN
MAINTAINBuy
Jun 1, 2026Ascendiant Capital
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$18.5K
bought · 1 insider
$0
sold · 0 insiders
−18.8%
vs their $0.1970 cost
DateInsiderTypeValue
Oct 22, 2026
Equels Thomas K
CEO & President
BUY$5.1K
Sep 17, 2026
Equels Thomas K
CEO & President
BUY$5.0K
Sep 16, 2026
Equels Thomas K
CEO & President
BUY$2.3K
Sep 15, 2026
Equels Thomas K
CEO & President
BUY$4.9K
Sep 14, 2026
Equels Thomas K
CEO & President
BUY$1.3K
Mar 12, 2026
Equels Thomas K
CEO & President
CONVERT25,000 sh
Mar 12, 2026
CHEMEROW DAVID I.
Director
CONVERT25,000 sh
Mar 12, 2026
CHEMEROW DAVID I.
Director
CONVERT25 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
1,407,198
shares short
-49.1%
vs prior settlement
1.0
days to cover
≈3.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 Insider
Equels Thomas K bought 31,250 shares
CEO & President @ $0.1630 ($5.1K)
Oct 5, 2026 Other
AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential
OCALA, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or th
Sep 30, 2026 SEC
AIM ImmunoTech Inc. filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for…
DEF 14A — Impact 3/10
Sep 22, 2026 Press
AIM ImmunoTech CEO issued a letter to shareholders addressing the recent FDA approval of daraxonrasib for pancreatic…
Impact 3/10
Sep 17, 2026 Insider
Equels Thomas K bought 24,000 shares
CEO & President @ $0.2080 ($5.0K)
Sep 16, 2026 Insider
Equels Thomas K bought 11,000 shares
CEO & President @ $0.2100 ($2.3K)
Sep 14, 2026 SEC
AIM ImmunoTech converted approximately $400,000 of its existing promissory note with Streeterville Capital into…
8-K — Impact 7/10
Aug 11, 2026 SEC
AIM ImmunoTech filed an 8-K furnishing a sponsored article by CEO Thomas Equels in Breaking Defense, promoting…
8-K — Impact 3/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 16, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Oct 5, 2026
Press release
AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential
OCALA, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent media…
Oct 1, 2026
Press release
AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data
Recent biotech media features focus on Ampligen’s potential to address immune resistance in metastatic pancreatic cancer and the clinical progress…
Sep 30, 2026
Press release
AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
Company highlights supportive survival observations, potential for biomarker-driven patient selection and upcoming Phase 2 DURIPANC milestones
Sep 30, 2026
Short interest
Short Interest: AIM down 49% to 1.4M shares
Settlement 2026-09-30 | Days to cover: 1.00 | ≈3.53% of shares outstanding (est.)
Sep 22, 2026
FDA
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib
Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancer

SecBot reports

20 filings · 10 press releases · 2 bullish · 12 bearish · 3 mixed · 3 neutral
All AIM filing & press-release reports (31)